A reader forwarded me a lab result from InVitaLab Medizindiagnostik and I have encoded as a new Lab on the site.

The report section on the microbiome is shown below

The Entry Form

As usual, I have tried to follow the sequence and do the best matches when things are fuzzy. In some case, like for E. Coli Rauhform, there was no match so it was omitted.

http://microbiomeprescription.com/labs/definition?key=C

Bottom Line

If you have a Lab result that is not a match for the existing ones, please send me a PDF of the results and I will add it. To see the current list of clinical labs supported visit:
http://microbiomeprescription.com/Labs

Also, I am working on the ability for user to save these lab reports so you can return and get updated suggestions as the database of modifiers grows.

This is a review of recent studies recorded on PubMed. The focus is on new information – so studies reporting prior information will rarely be mentioned. Cases are now being reported from Nepal to New York City proper.

• Microbiological features distinguishing Lyme disease and relapsing fever spirochetes.[2018]
  • “The recent proposal of splitting the genus Borrelia into two genera in the newly formed family of Borreliaceae, i. e. Borrelia and Borreliella “
• Lyme Disease in 2018: What Is New (and What Is Not).
  • 
• Cost-effectiveness of a potential anti-tick vaccine with combined protection against Lyme borreliosis and tick-borne encephalitis in Slovenia[2018].
  • “A wholesale price for a vaccine shot of €9.13 would lead to cost savings followed by health gains for the vaccination strategy.”
  • Omics and bioinformatics applied to vaccine development against Borrelia.[2018]
  • Design of a Lyme Disease Vaccine as an Active Learning Approach in a Novel Interdisciplinary Graduate-Level Course.[2017]
• The Persistent Lyme Disease: “True Chronic Lyme Disease” rather than “Post-treatment Lyme Disease Syndrome”[2018].
  • “A meta-analysis of test accuracy reported a sensitivity of only 59.5%, varying from 30.6%–86.2%.[5] Antibiotic testing is necessary to reach Lyme disease final diagnosis, namely in patients presenting with negative tests and a suggestive clinical presentation.”
  • “A new approach with antibiotics was initiated: ceftriaxone (2 g/day for 1 month) followed by doxycycline (200 mg twice a day) associated with hydroxychloroquine 200 (once a day). Two months later, after a quick improvement, the patient exhibited no symptoms. “
• Identifying vancomycin as an effective antibiotic for killing Borrelia burgdorferi[2018].
  • “doxycycline, a standard of care for uncomplicated acute infection, did not clear the pathogen. By contrast, both ceftriaxone and vancomycin cleared the infection.”
• Infectious Mononucleosis and Lyme Disease as Confounding Diagnoses: A Report of 2 Cases [2018].
  • “Significant cross-reactivity is known to occur between Lyme and EBV serologic assays complicating the diagnosis. “
  • Comment: i.e. you may have EBV and get a positive Lyme results. With CFS reactivation of prior EBV infection being well known – Telling CFS from Lyme lack any reliable tests.
• Metabolites of prostaglandin synthases as potential biomarkers of Lyme disease severity and symptom resolution[2018].
  • “subjects with Lyme meningitis, Lyme arthritis (LA) and antibiotic-refractory LA had increased levels of an array of PGs and lipid mediators (e.g., LTB_4, 8-isoPGF_2α, and phospholipases A₂ activity). ‘
  • Identification of Urine Metabolites as Biomarkers of Early Lyme Disease [2018].
    • “Linear discriminant analyses demonstrated that individual metabolic biosignatures can correctly discriminate ELD from the other patient groups with accuracies of 71 to 100%. “

• Secondary dementia due to Lyme neuroborreliosis.[2018]
• Cognitive Decline in Post-treatment Lyme Disease Syndrome. [2018]
• Neuropsychiatric Lyme Borreliosis: An Overview with a Focus on a Specialty Psychiatrist’s Clinical Practice[2018].
  • “usually presenting with significant comorbidity which may include developmental disorders, autism spectrum disorders, schizoaffective disorders, bipolar disorder, depression, anxiety disorders (panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder, intrusive symptoms), eating disorders, decreased libido, sleep disorders, addiction, opioid addiction, cognitive impairments, dementia, seizure disorders, suicide, violence, anhedonia, depersonalization, dissociative episodes, derealization and other impairments. “
  • Aggressiveness, violence, homicidality, homicide, and Lyme disease.[2018]
  • Risk Factors for Clinician-Diagnosed Lyme Arthritis, Facial Palsy, Carditis, and Meningitis in Patients From High-Incidence States.[2017]
• Ophthalmological findings in neuroborreliosis – a prospective study performed in western Sweden.[2018]
  • “Facial palsy with palpebral diastasis was a common finding. Onset of diplopia and/or sixth nerve affection may be a first sign of neuroborreliosis. Number of ophthalmological findings was correlated with the CSF antibody titre”
  • Outcome of facial palsy from Lyme disease in prospectively followed patients who had received corticosteroids [2018].
• The Emergence of a Forgotten Entity: Dermatomyositis-like Presentation of Lyme Disease in Rural Wisconsin.[2018]

This is a review of recent studies recorded on PubMed. The focus is on new information – so studies reporting prior information will rarely be mentioned.

• The effects of warm water immersion on blood pressure, heart rate and heart rate variability in people with chronic fatigue syndrome[2018].
  • Temporary relief.
  • “Chronic fatigue syndrome (CFS) is a central sensitisation syndrome with abnormalities in autonomic regulation of blood pressure (BP), heart rate (HR) and heart rate variability (HRV).”
  • Cerebral blood flow and heart rate variability predict fatigue severity in patients with chronic fatigue syndrome. [2018]
• Dry eye syndrome and the subsequent risk of chronic fatigue syndrome-a prospective population-based study in Taiwan.
  • 2x greater risk of CFS
• Chronic fatigue syndrome patients have alterations in their oral microbiome composition and function.
  • “CFS patients had a higher relative abundance of Fusobacteria compared with healthy controls. Further, the genera Leptotrichia, Prevotella, and Fusobacterium were enriched and Haemophilus, Veillonella, and Porphyromonas were depleted in CFS patients compared to healthy controls. “
• Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons [2018].
  • “Results support the notion that specific microorganisms interact with some ME/CFS symptoms and offer promise for the therapeutic potential of targeting gut dysbiosis in this population. Streptococcus spp. are not the primary or sole producers of D-lactate. Further investigation of lactate concentrations are needed to elucidate any role of D-lactate in this population”
  • 400 mg of erythromycin twice daily
• Visual Aspects of Reading Performance in Myalgic Encephalomyelitis (ME)[2018].
  • “vision-related reading difficulty belongs to a class of measureable symptoms for ME/CFS patients.”
• The expression signature of very long non-coding RNA in myalgic encephalomyelitis/chronic fatigue syndrome [2018].
  • “LncRNAs NTT, MIAT and EmX2OS levels were found to be significantly elevated in ME/CFS patients as compared with healthy controls. Furthermore, NTT and EmX2OS levels increased with disease severity. “
• Multidisciplinary rehabilitation treatment is not effective for myalgic encephalomyelitis/chronic fatigue syndrome: A review of the FatiGo trial[2018].
• Cognitive-behavioural therapy for chronic fatigue syndrome: neither efficacious nor safe[2018].
• Higher Prevalence of “Low T3 Syndrome” in Patients With Chronic Fatigue Syndrome: A Case-Control Study[2018].
• Differentiating Multiple Sclerosis from Myalgic Encephalomyelitis and Chronic Fatigue Syndrome [2017].
  • “Those individuals with ME or CFS reported significantly more functional limitations and significantly more severe symptoms than those with MS.”

Bottom Line

It was nice reading of success addressing the lactic acid aspect of CFS with antibiotics (erythromycin – a macrolide) on patients with high streptococcus count. It was the coming together of multiple threads — if you want to understand better or get a better background, see these posts:

• Approaches to D-Lactic Acidosis

• Staphylococcus aureus –  the CFS maintainer?

• Why Jadin’s Antibiotics Protocol usually work — Pasteur Institute got the solution right and the explanation wrong?

I’ve just added an “A priori” page.

A Priori relating to or denoting reasoning or knowledge that proceeds from theoretical deduction rather than from observation or experience.

In simpler words — if you have condition X and the results of the studies are correct, then we can make some suggestions assuming your microbiome shifts are similar to those reported in the literature.

Conditions Profiles Available

• ADHD
• Allergies
• Alzheimer’s disease
• Amyotrophic lateral sclerosis (ALS) Motor Neuron
• Autism
• Autoimmune Disease
• Brain Trauma
• Chronic Fatigue Syndrome
• Crohn’s Disease
• Depression
• Gout
• Hashimoto’s thyroiditis
• High Blood Pressure
• Histamine Issues
• Inflammatory Bowel Disease
• Irritable Bowel Syndrome
• Metabolic Syndrome
• Mood Disorders
• Multiple Sclerosis
• Parkinson’s Disease
• Rheumatoid arthritis
• Sclerosis
• Sjögren syndrome
• Small Intestinal Bacterial Overgrowth (SIBO)
• Stress / post-traumatic stress disorder
• Systemic Lupus Erythematosus
• Type 2 Diabetes
• Ulcerative colitis

When you click on one of these, you will be taken to the suggestion page which allows you to filter suggestions in many different ways.

For example, for Mood disorders:

This is NOT medical advice — Just Educational

The suggestions are based on PubMed studies (with links provided). Often, these may be better than “off-the-cuff” suggestions made by some medical professionals.

This is an education post to facilitate discussing this approach with your medical professionals. It is not medical advice for the treatment of any medical condition. Always consult with your medical professional before doing any  changes of diet, supplements or activity. Some items cites may interfere with prescription medicines.

This is a review of recent studies recorded on PubMed. The focus is on new information – so studies reporting prior information will rarely be mentioned.

• Antibiotics: a risk factor for irritable bowel syndrome in a population-based cohort [2018].
  • “the relative risk of IBS in 2013 related with use of antibiotics was 1.9”
• Irritable Bowel Syndrome Is Associated with an Increased Risk of Dementia: A Nationwide Population-Based Study [2016].
  • “patients with IBS were also more likely to develop either non- Alzheimer’s disease (AD) dementia or Alzheimer’s disease”
• Irritable bowel syndrome correlates with increased risk of Parkinson’s disease in Taiwan[2014].
  • ” The overall incidence of Parkinson’s disease in the IBS group was 1.76-fold higher than that in the non-IBS group”
• Aloe Vera is Effective and Safe in Short-term Treatment of Irritable Bowel Syndrome: A Systematic Review and Meta-analysis [2018].
  • “AV is effective and safe for the treatment of patients with IBS compared to placebo.”
• Association between Allergic Diseases and Irritable Bowel Syndrome: A Retrospective Study[2018].
  • “chronic urticaria  patients had a trend of increase in the detection of IBS compared to controls  (4.8x more often)”
• Relationships of Microbiome Markers With Extraintestinal, Psychological Distress and Gastrointestinal Symptoms, and Quality of Life in Women With Irritable Bowel Syndrome [2018].
  • “Lower extraintestinal pain was associated with increased Rikenellaceae, Christensenellaceae, Dehalobabacteriaceae, Oscillospiraceae, Mogibacteriaceae, Ruminococcaceae, Sutterellaceae, Desulfovibrionaceae, and Erysipelotrichaceae abundances.”
• Association between SERT insertion/deletion polymorphism and the risk of irritable bowel syndrome: A meta-analysis based on 7039 subjects [2018].
  • “Our findings indicated that the SERT insertion/deletion polymorphism may serve as a genetic biomarker of IBS in Asians and Caucasians.”
• Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome 2018].
  • “In patients with IBS-D with intestinal hyperpermeability following an enteric infection, oral dietary glutamine supplements dramatically and safely reduced all major IBS-related endpoints. “
• A microbial signature of psychological distress in irritable bowel syndrome [2018].
  • “Depression was negatively associated with Lachnospiraceae abundance (Spearman’s rho= -0.58, q= .018). Patients exceeding thresholds of distress, anxiety, depression and stress perception showed significantly higher abundances of Proteobacteria (q= .020 to .036). Patients with anxiety were characterized by elevated Bacteroidaceae (q= .036). “
• Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome.[2018]
  • “At the genus level, Lachnospira (P = 0.036), Parasutterella (P = 0.033), Lachnospiraceae_UCG-010 (P = 0.026), Ruminococcaceae_UCG-003 (P = 0.023), Lactobacillus (P = 0.021), Turicibacter (P = 0.022), Enterococcus (P = 0.002), Weissella (P = 0.048), Oxalobacter (P = 0.048), Oceanobacillus (P = 0.011), and Lachnospiraceae_NK4A136_group (P = 0.026) were significantly less abundant in IBS-D patients, while Faecalitalea (P = 0.012) was increased in IBS-D patients”
• Systematic review and meta-analysis: Efficacy of patented probiotic, VSL#3, in irritable bowel syndrome [2018].
  • ” there was a trend toward improvement in overall response with VSL#3, but no clear evidence effectiveness for IBS.”
• Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double-blind, placebo controlled, multi-centre, pilot clinical study.
  • “B. coagulans MTCC 5856 showed robust efficacy for the treatment of patients experiencing IBS symptoms with major depressive disorder. The improvement in depression and IBS symptoms was statistically significant and clinically meaningful. “
• Effect of Probiotic Administration Immediately and 1 Month after Colonoscopy in Diarrhea-predominant Irritable Bowel Syndrome Patients [2018].
  • “Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Bifidobacterium breve, Bifidobacterium longum, and Streptococcus thermophilus”
  • “Our results showed the beneficial effect of probiotics on symptoms of IBS, including stool consistency and frequency, production of gas, abdominal pain, and flatulence.”
  • IMHO Lactobacillus casei andBifidobacterium are likely the most beneficial one
• Microstructural White Matter Abnormalities in the Dorsal Cingulum of Adolescents with IBS.[2018]
• White Matter Microstructural Similarity and Diversity of Functional Constipation and Constipation-predominant Irritable Bowel Syndrome [2018].

Bottom Line

We continue to find more and more any significant studies on microbiome shifts for IBS. A microbiome dysbiosis model fits well — including the increased risk of progression into dementia (which have greater dysbiosis).

I have updated the IBS Profile on http://microbiomeprescription.azurewebsites.net

Addendum: HOLIGOS for sale in US (Finally!):

It’s Human Milk Oligosaccharides — to be more precise, bio-identical oligosaccharides  which would be found in mother’s milk. We all know that a child that is breast fed usually grows up with less health problems than a bottle fed one.

See https://cfsremission.wordpress.com/2018/08/02/an-awesome-clinical-trial-for-ibs-folks/